Disc Medicine, Inc.
Disc Medicine, Inc. (Nasdaq: DISC) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for patients with serious hematologic diseases. The company's website is www.discmedicine.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Disc Medicine, Inc. does
In the company’s own words
Disc Medicine, Inc. (Nasdaq: DISC) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for patients with serious hematologic diseases. The company's website is www.discmedicine.com.
The company's pipeline targets fundamental biological pathways associated with red blood cell formation and function, specifically heme biosynthesis and iron homeostasis. Disc Medicine's lead product candidate, bitopertin, is an oral selective inhibitor of glycine transporter 1 designed to reduce the accumulation of toxic metabolites in patients with erythropoietic porphyrias, including erythropoietic protoporphyria and X-linked protoporphyria. The company submitted a New Drug Application for accelerated approval of bitopertin in September 2025 and received a complete response letter from the FDA in February 2026. A Phase 3 clinical trial, APOLLO, is underway with topline data expected in the fourth quarter of 2026.
The company's iron homeostasis portfolio includes DISC-0974, licensed from AbbVie, which is designed to suppress hepcidin production and increase serum iron levels for treating anemia associated with myelofibrosis and inflammatory bowel disease. DISC-3405, licensed from Mabwell Therapeutics, is a monoclonal antibody against transmembrane serine protease 6 being developed for polycythemia vera and sickle cell disease. The company is also developing DISC-0998, a preclinical anti-hemojuvelin monoclonal antibody for anemia associated with inflammatory diseases.
Disc Medicine was founded in 2017 and has assembled a management team with extensive experience developing and commercializing transformative therapies for hematologic diseases. The company's team has previously worked at leading biotechnology and pharmaceutical companies including Acceleron Pharma, Agios Pharmaceuticals, Bristol-Myers Squibb, CRISPR Therapeutics, FibroGen, Genzyme, Johnson & Johnson, Merck, Pfizer, Vertex Pharmaceuticals, and others. The company holds exclusive worldwide licenses for bitopertin, DISC-0974, and DISC-0998, and exclusive rights for DISC-3405 outside Greater China and Southeast Asia.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1816736
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Disc Medicine, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Disc Medicine, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Disc Medicine, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Disc Medicine, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Disc Medicine, Inc.'s last four quarterly filings that the numbers alone won't show?”